April Japanese price cut a mixed bag of give and take
This article was originally published in Scrip
The official release of Japan's new reimbursement tariff showing the revised prices for individual drugs that will come into effect on 1 April reveals a complex mixture of relative impact for products and companies, although as usual the figures are overwhelmingly negative.
You may also be interested in...
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Japan coordinates initiative to improve regional early-stage development of novel cancer therapies, which will work both with the industry and independently to improve access.